Bronchiectasis-Pipeline Review, H1 2015

Bronchiectasis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6611IDB
  • |
  • Pages: 74
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bronchiectasis-Pipeline Review, H1 2015


Global Markets Direct's, 'Bronchiectasis-Pipeline Review, H1 2015', provides an overview of the Bronchiectasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bronchiectasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bronchiectasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bronchiectasis Overview 7

Therapeutics Development 8

Pipeline Products for Bronchiectasis-Overview 8

Pipeline Products for Bronchiectasis-Comparative Analysis 9

Bronchiectasis-Therapeutics under Development by Companies 10

Bronchiectasis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Bronchiectasis-Products under Development by Companies 14

Bronchiectasis-Companies Involved in Therapeutics Development 15

Alitair Pharmaceuticals, Inc. 15

Bayer AG 16

Clarassance, Inc. 17

GlaxoSmithKline plc 18

Grifols, S.A. 19

Kamada Ltd. 20

Nostrum Pharmaceuticals, LLC 21

Pulmatrix, Inc. 22

Recipharm AB 23

Savara Inc. 24

Serendex Pharmaceuticals A/S 25

Bronchiectasis-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

alpha-1 proteinase inhibitor (human) second generation-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ALT-07-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ALT-09-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ARD-3150-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

BAY-858501-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CG-1011-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ciprofloxacin-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

dapsone-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

erdosteine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

GSK-2793660-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Leukotriene B4-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

levofloxacin-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

molgramostim-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Recombinant Human Follistatin-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

vancomycin hydrochloride-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Bronchiectasis-Recent Pipeline Updates 58

Bronchiectasis-Dormant Projects 64

Bronchiectasis-Discontinued Products 65

Bronchiectasis-Product Development Milestones 66

Featured News & Press Releases 66

Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia 66

Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation 66

Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis 66

Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 67

Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 68

May 20, 2014: FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic 69

May 05, 2014: Pulmatrix Presents Preclinical Data on iSPERSE Inhaled Antibiotics at the 2014 Respiratory Drug Delivery Conference 70

Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA 70

Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis 71

Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 71

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

Number of Products under Development for Bronchiectasis, H1 2015 8

Number of Products under Development for Bronchiectasis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Bronchiectasis-Pipeline by Alitair Pharmaceuticals, Inc., H1 2015 15

Bronchiectasis-Pipeline by Bayer AG, H1 2015 16

Bronchiectasis-Pipeline by Clarassance, Inc., H1 2015 17

Bronchiectasis-Pipeline by GlaxoSmithKline plc, H1 2015 18

Bronchiectasis-Pipeline by Grifols, S.A., H1 2015 19

Bronchiectasis-Pipeline by Kamada Ltd., H1 2015 20

Bronchiectasis-Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 21

Bronchiectasis-Pipeline by Pulmatrix, Inc., H1 2015 22

Bronchiectasis-Pipeline by Recipharm AB, H1 2015 23

Bronchiectasis-Pipeline by Savara Inc., H1 2015 24

Bronchiectasis-Pipeline by Serendex Pharmaceuticals A/S, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Bronchiectasis Therapeutics-Recent Pipeline Updates, H1 2015 58

Bronchiectasis-Dormant Projects, H1 2015 64

Bronchiectasis-Discontinued Products, H1 2015 65

List of Figures

Number of Products under Development for Bronchiectasis, H1 2015 8

Number of Products under Development for Bronchiectasis-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Alitair Pharmaceuticals, Inc.

Bayer AG

Clarassance, Inc.

GlaxoSmithKline plc

Grifols, S.A.

Kamada Ltd.

Nostrum Pharmaceuticals, LLC

Pulmatrix, Inc.

Recipharm AB

Savara Inc.

Serendex Pharmaceuticals A/S

Bronchiectasis Therapeutic Products under Development, Key Players in Bronchiectasis Therapeutics, Bronchiectasis Pipeline Overview, Bronchiectasis Pipeline, Bronchiectasis Pipeline Assessment

select a license
Single User License
USD 2000 INR 144740
Site License
USD 4000 INR 289480
Corporate User License
USD 6000 INR 434220



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]